Drug Discovery for Malaria: a Very Challenging and Timely Endeavor

Overview

Journal Curr Opin Chem Biol

Publisher Elsevier

Specialty Biochemistry

Date 2007 Sep 1

PMID 17761335

Citations 41

Authors

Michael H Gelb

Affiliations

Soon will be listed here.

Abstract

The prevalence of resistance to known antimalarial drugs has resulted in the expansion of antimalarial drug discovery efforts. Academic and nonprofit institutions are partnering with the pharmaceutical industry to develop new antimalarial drugs. Several new antimalarial agents are undergoing clinical trials, mainly those resurrected from previous antimalarial drug discovery programs. Novel antimalarials are being advanced through the drug development process, of course, with the anticipated high failure rate typical of drug discovery. Many of these are summarized in this review. Mechanisms for funding antimalarial drug discovery and genomic information to aid drug target selection have never been better. It remains to be seen whether ongoing efforts will be sufficient for reducing malaria burden in the developing world.

Citing Articles

Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.

Bhargava S, Deshmukh R, Dewangan H Curr Pharm Des. 2024; 31(3):203-218.

PMID: 39279710 DOI: 10.2174/0113816128321468240828103439.

Antimalarial and immunomodulatory potential of chalcone derivatives in experimental model of malaria.

Sinha S, Medhi B, Radotra B, Batovska D, Markova N, Bhalla A BMC Complement Med Ther. 2022; 22(1):330.

PMID: 36510199 PMC: 9743746. DOI: 10.1186/s12906-022-03777-w.

Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review.

Hassan M, Awan F, Naz A, deAndres-Galiana E, Alvarez O, Cernea A Int J Mol Sci. 2022; 23(9).

PMID: 35563034 PMC: 9104788. DOI: 10.3390/ijms23094645.

Target-Based Virtual Screening of Natural Compounds Identifies a Potent Antimalarial With Selective Falcipain-2 Inhibitory Activity.

Uddin A, Gupta S, Mohammad T, Shahi D, Hussain A, Alajmi M Front Pharmacol. 2022; 13:850176.

PMID: 35462917 PMC: 9020225. DOI: 10.3389/fphar.2022.850176.

Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria.

Gujjari L, Kalani H, Pindiprolu S, Arakareddy B, Yadagiri G Parasite Epidemiol Control. 2022; 17:e00244.

PMID: 35243049 PMC: 8866151. DOI: 10.1016/j.parepi.2022.e00244.

References

Vennerstrom J, Arbe-Barnes S, Brun R, Charman S, Chiu F, Chollet J . Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004; 430(7002):900-4. DOI: 10.1038/nature02779. View

Eastman R, White J, Hucke O, Bauer K, Yokoyama K, Nallan L . Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005; 280(14):13554-9. DOI: 10.1074/jbc.M413556200. View

Vial H, Wein S, Farenc C, Kocken C, Nicolas O, Ancelin M . Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc Natl Acad Sci U S A. 2004; 101(43):15458-63. PMC: 523447. DOI: 10.1073/pnas.0404037101. View

Madrid P, Wilson N, DeRisi J, Guy R . Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. J Comb Chem. 2004; 6(3):437-42. PMC: 1467020. DOI: 10.1021/cc0340473. View

Calas M, Ancelin M, Cordina G, Portefaix P, Piquet G, Vial H . Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem. 2000; 43(3):505-16. DOI: 10.1021/jm9911027. View

Uhlemann A, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, A Zuniga F . A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol. 2005; 12(7):628-9. DOI: 10.1038/nsmb947. View

Ro D, Paradise E, Ouellet M, Fisher K, Newman K, Ndungu J . Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature. 2006; 440(7086):940-3. DOI: 10.1038/nature04640. View

Croft S . Public-private partnership: from there to here. Trans R Soc Trop Med Hyg. 2005; 99 Suppl 1:S9-14. DOI: 10.1016/j.trstmh.2005.06.008. View

Yeramian P, Meshnick S, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N . Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis. 2005; 192(2):319-22. DOI: 10.1086/430928. View

10.

Mathis A, Holman J, Sturk L, Ismail M, Boykin D, Tidwell R . Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob Agents Chemother. 2006; 50(6):2185-91. PMC: 1479144. DOI: 10.1128/AAC.00192-06. View

11.

Bathurst I, Hentschel C . Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol. 2006; 22(7):301-7. DOI: 10.1016/j.pt.2006.05.011. View

12.

Nallan L, Bauer K, Bendale P, Rivas K, Yokoyama K, Horney C . Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005; 48(11):3704-13. DOI: 10.1021/jm0491039. View

13.

Anderson M, Sherrill J, Madrid P, Liou A, Weisman J, DeRisi J . Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. Bioorg Med Chem. 2005; 14(2):334-43. PMC: 1474025. DOI: 10.1016/j.bmc.2005.08.017. View

14.

Wengelnik K, Vidal V, Ancelin M, Cathiard A, Morgat J, Kocken C . A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science. 2002; 295(5558):1311-4. DOI: 10.1126/science.1067236. View

15.

Posner G, ONeill P . Knowledge of the proposed chemical mechanism of action and cytochrome p450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides. Acc Chem Res. 2004; 37(6):397-404. DOI: 10.1021/ar020227u. View

16.

Eckstein-Ludwig U, Webb R, Van Goethem I, East J, Lee A, Kimura M . Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003; 424(6951):957-61. DOI: 10.1038/nature01813. View

17.

ONeill P, Mukhtar A, Stocks P, Randle L, Hindley S, Ward S . Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem. 2003; 46(23):4933-45. DOI: 10.1021/jm030796n. View

18.

Paik I, Xie S, Shapiro T, Labonte T, Narducci Sarjeant A, Baege A . Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. J Med Chem. 2006; 49(9):2731-4. DOI: 10.1021/jm058288w. View

19.

Nwaka S, Hudson A . Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006; 5(11):941-55. DOI: 10.1038/nrd2144. View

20.

Wang M, Saulter J, Usuki E, Cheung Y, Hall M, Bridges A . CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos. 2006; 34(12):1985-94. PMC: 2077835. DOI: 10.1124/dmd.106.010587. View